UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Constellation Pharmaceuticals, Inc.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE PER SHARE

(Title of Class of Securities)

210373106

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 210373106		SCHEDULE 13G		Page 2 of 11 Pages


CUSIP No. 210373106		SCHEDULE 13G		Page 3 of 11 Pages


CUSIP No. 210373106		SCHEDULE 13G		Page 4 of 11 Pages


CUSIP No. 210373106		SCHEDULE 13G		Page 5 of 11 Pages

(1)	The percent of class was calculated based on 47,575,521 shares of common stock issued and outstanding as of October 23,2020, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2020.


CUSIP No. 210373106		SCHEDULE 13G		Page 6 of 11 Pages

(1)	The percent of class was calculated based on 47,575,521 shares of common stock issued and outstanding as of October 23,2020, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2020.


CUSIP No. 210373106		SCHEDULE 13G		Page 7 of 11 Pages

(1)	Consists of (i) 151,019 shares of common stock held directly by Dr. Tepper and (ii) 13,171 shares issuable to Dr. Tepper upon exercise of options exercisable within 60 days of December 31, 2020.

(2)

The percent of class was calculated based on 47,575,521 shares of common stock issued and outstanding as of October 23,2020, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2020 and 13,171 shares of common stock underlying the options that are exercisable within 60 days of December 31, 2020 which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i)).


CUSIP No. 210373106		SCHEDULE 13G		Page 8 of 11 Pages


Item 1.		Issuer

	(a)	Name of Issuer:

		Constellation Pharmaceuticals, Inc. (the “Issuer”)

	(b)	Address of Issuer’s Principal Executive Offices:

		215 First Street, Suite 200 Cambridge, MA 02142

Item 2.		Filing Person

	(a) – (c)	Name of Persons Filing; Address; Citizenship:

		(i) Third Rock Ventures, L.P. (“TRV”); (ii) Third Rock Ventures GP, L.P. (“TRV GP”), which is the sole general partner of TRV; (iii) TRV GP, LLC (“TRV GP LLC”), which is the sole general partner of TRV GP; (iv) Mark Levin (“Levin”), a managing member of TRV GP LLC; (v) Kevin P. Starr (“Starr”), a managing member of TRV GP LLC; and (vi) Robert I. Tepper (“Tepper,” and collectively with TRV, TRV GP, TRV GP LLC, Levin and Starr, the “Reporting Persons”), a managing member of TRV GP LLC. The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 29 Newbury Street, 3rd Floor, Boston, MA 02116. Each of TRV and TRV GP is a Delaware limited partnership. TRV GP LLC is a Delaware limited liability company. Levin, Tepper and Starr are United States citizens.

	(d)	Title of Class of Securities:

		Common stock, $0.0001 par value per share, (the “Common Stock”)

	(e)	CUSIP Number: 210373106

Item 3.	If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

	(a)	☐	Broker or dealer registered under Section 15 of the Act;

	(b)	☐	Bank as defined in Section 3(a)(6) of the Act;

	(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act;

	(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940;

	(e)	☐	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

	(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

	(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

	(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

	(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

	(j)	☐	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

	(k)	☐	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


CUSIP No. 210373106		SCHEDULE 13G		Page 9 of 11 Pages


								If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


Item 4.	Ownership.

	(a) and (b) Amount beneficially owned:

		(i)	TRV directly owns zero (0) shares of Common Stock.

		(ii)	TRV GP directly owns zero (0) shares of Common Stock.

		(iii)	TRV GP LLC directly owns zero (0) shares of Common Stock.

		(iv)	As of December 31, 2020, Levin directly owns 125,020 shares of Common Stock, which represents approximately 0.3% of the outstanding shares of Common Stock.

		(v)	As of December 31, 2020, Starr directly owns 151,021 shares of Common Stock, which represents approximately 0.3% of the outstanding shares of Common Stock.

		(vi)	As of December 31, 2020, Tepper directly owns (i) 151,019 shares of Common Stock and (ii) options to purchase 13,171 shares of Common Stock exercisable within 60 days after December 31, 2020, which represents approximately 0.3% of the outstanding shares of Common Stock.

	(c)	Number of shares as to which such person has:


	Number of Shares of Common Stock
Reporting Person	(i)		(ii)		(iii)		(iv)
Levin		125,020		0		125,020		0
Starr		151,021		0		151,021		0
Tepper		164,190		0		164,190		0


		(i) Sole power to vote or direct the vote (ii) Shared power to vote or to direct the vote (iii) Sole power to dispose or to direct the disposition of (iv) Shared power to dispose or to direct the disposition of

		The percent of class was calculated based on 47,575,521 shares of common stock issued and outstanding as of October 23,2020, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2020.

Item 5.		Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

Item 6.		Ownership of More than Five Percent on Behalf of Another Person. Not applicable.


CUSIP No. 210373106		SCHEDULE 13G		Page 10 of 11 Pages


Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.

Item 8.		Identification and Classification of Members of the Group. Not applicable.

Item 9.		Notice of Dissolution of Group. Not applicable.

Item 10.		Certification. Not applicable.


CUSIP No. 210373106		SCHEDULE 13G		Page 11 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 16, 2021


THIRD ROCK VENTURES, L.P.

By:		THIRD ROCK VENTURES GP, L.P.,
General Partner

By: TRV GP, LLC,
General Partner

By:		/s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

THIRD ROCK VENTURES GP, L.P.

By: TRV GP, LLC,
General Partner

By:		/s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

TRV GP, LLC

By:		/s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

MARK LEVIN

/s/ Kevin Gillis, As attorney-in-fact
Mark Levin

KEVIN P. STARR

/s/ Kevin Gillis, As attorney-in-fact
Kevin P. Starr

ROBERT I. TEPPER

/s/ Kevin Gillis, As attorney-in-fact
Robert I. Tepper

EXHIBIT 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

Each of the undersigned may execute this power of attorney in separate counterparts, and each counterpart shall be deemed to be an original instrument. This agreement shall be effective as to each of the undersigned as of the date signed by that signatory.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 16th day of January, 2014.

/s/ Mark Levin

Mark Levin

/s/ Kevin P. Starr

Kevin P. Starr

/s/ Robert I. Tepper

Robert I. Tepper

EXHIBIT 99.1

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: February 16, 2021


THIRD ROCK VENTURES, L.P.

By:		THIRD ROCK VENTURES GP, L.P.,
General Partner

By:		TRV GP, LLC,
General Partner

By:		/s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

THIRD ROCK VENTURES GP, L.P.

By:		TRV GP, LLC,
General Partner

By:		/s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

TRV GP, LLC

By:		/s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

MARK LEVIN

/s/ Kevin Gillis, As attorney-in-fact
Mark Levin

KEVIN P. STARR

/s/ Kevin Gillis, As attorney-in-fact
Kevin P. Starr

ROBERT I. TEPPER

/s/ Kevin Gillis, As attorney-in-fact
Robert I. Tepper

NAMES OF REPORTING PERSONS

Third Rock Ventures, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

CONSTELLATION PHARMACEUTICALS INC SC 13G/A